Results 211 to 220 of about 37,693 (353)

A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear.
Alexandra Katz, Aidan Shulkin, Asmaa Housni, Amélie Roy‐Fleming, Rémi Rabasa‐Lhoret, Jean‐Francois Yale, Michael A. Tsoukas, Tricia M. Peters, Anne‐Sophie Brazeau   +8 more
wiley   +1 more source

The Incidence and Correlation of Renal Pathologies Based on 14-Year Kidney Biopsy Material: A Retrospective Single-Centre Study in Poland. [PDF]

J Clin Med
Benc K, Tabaka E, Pabian W, Pisarek D, Letachowicz K, Gołębiowski T, Kuriata-Kordek M, Kanafa M, Jerzak P, Skalec K, Donizy P, Hałoń A, Konieczny A, Banasik M.   +13 more
europepmc   +1 more source

The predictive value of neutrophil-to-lymphocyte ratio for the occurrence, progression, and mortality of diabetic nephropathy: a systematic review and meta-analysis. [PDF]

Sci Rep
Liu H, Chen L, Zhu J, Zhang Z, Nie H, Tan C, Gong W, Ai Y, Yuan X, Zhang S, He X, Liu X, Cai P, Song Y.   +13 more
europepmc   +1 more source

Association between daily steps, diabetes management and health indicators in people living with type 1 diabetes: A cross‐sectional study from the BETTER registry

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims In people with type 1 diabetes, physical activity provides important health benefits but is mainly limited by fear of hypoglycaemia. Daily step count is a simple indicator of ambulatory activity. This study examined associations between step count and health indicators.
Thélo I. Garré, Capucine G. Guédet, Laure Alexandre‐Heymann, Virginie Messier, Valérie Boudreau, Semah Tagougui, Claude Laforest, Anne‐Sophie Brazeau, Rémi Rabasa‐Lhoret, Jane E. Yardley   +9 more
wiley   +1 more source

Protective mechanism of apigenin in diabetic nephropathy is related to its regulation of miR-423-5P-USF2 axis.

, 2021
Yi Hou, Yan Zhang, Sitong Lin, Yue Yu, Liu Yang, Lei Li, Wenxiang Wang   +6 more
openalex   +1 more source

Blockade of Endothelial-Mesenchymal Transition by a Smad3 Inhibitor Delays the Early Development of Streptozotocin-Induced Diabetic Nephropathy [PDF]

, 2010
Jinhua Li, Xinli Qu, Jun Yao, Georgina Caruana, Sharon D. Ricardo, Yasuhiko Yamamoto, Hiroshi Yamamoto, John F. Bertram   +7 more
openalex   +1 more source

miRNAs in Glomerular Diseases: From Pathogenic Insight to Therapeutic Potential: A Narrative Review. [PDF]

Cells
Apetrii M, Costache AD, Costache Enache II, Voroneanu L, Covic AS, Kanbay M, Scripcariu DV, Covic A.   +7 more
europepmc   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino, Masato Kasahara, Ryuzo Takashima, Shu Kasama, Naoki Ozu, Hyohun Park, Qingxing Chen, Kazuhiko Tsuruya, Mayu Tochiya, Yoko Omura‐Ohata, Tamiko Tamanaha, Michio Noguchi, Takeshi Aiba, Fumiki Yoshihara, Kiminori Hosoda   +14 more
wiley   +1 more source

Construction and evaluation of STZ-induced diabetes and diabetic kidney disease models in C57BL/6J mice. [PDF]

Front Endocrinol (Lausanne)
Li H, Qin F, Zheng S, Wu J, Lin S, Gao X, Liu Y.   +6 more
europepmc   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source